ReviewJournal of the American Society of Nephrology : JASN2016
Hepatitis C Virus Infection in Chronic Kidney Disease.
Review in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Skin cancer in patients who are co-infected with HIV/ HBV or HIV/HCV: a systematic review.Archives of dermatological research · 2024Pooled it
- Coincidence of HCV and chronic kidney disease-a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Viral Infections in Kidney Transplant Recipients: Current Practice and Updates.Journal of clinical medicine · 2026Review
- Factors associated with chronic kidney disease among patients with hepatitis c infection attending Kigeme district hospital, Rwanda.Scientific reports · 2026Article
- Unraveling the mechanism of tetracycline-induced renal injury: an evaluation of drug safety based on network toxicology and molecular dynamics simulations.BMC pharmacology & toxicology · 2025Article
- High risk of hepatic complications in kidney transplantation with chronic hepatitis C virus infection.Scientific reports · 2025Article
- Article
- Renal Manifestations of Chronic Hepatitis C: A Review.Journal of clinical medicine · 2024Review
- Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.Saudi medical journal · 2024Article
- Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational StudyBalkan medical journal · 2023Observational
- Molecular characterization and genotyping of hepatitis C virus from Sudanese end-stage renal disease patients on haemodialysis.BMC infectious diseases · 2022Article
- Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection.Journal of clinical medicine · 2021Article
- Use of disease embedding technique to predict the risk of progression to end-stage renal disease.Journal of biomedical informatics · 2020Article
- Article
- Translation and validation study of the Polish version of the Brief Hepatitis C Knowledge Scale.PloS one · 2020Article
- High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents.International urology and nephrology · 2019Observational
- Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.Advances in chronic kidney disease · 2019Review
- Living kidney donation in individuals with hepatitis C and HIV infection: rationale and emerging evidence.Current transplantation reports · 2019Article
- HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents.Frontiers in medicine · 2019Review
- Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients.BioMed research international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soon after the hepatitis C virus (HCV) was identified in 1989, it was recognized that the prevalence of infection in patients with ESRD far exceeded that in the general population. Infection with HCV predisposes to the hepatic complications of cirrhosis and hepatocellular carcinoma. However, important extrahepatic manifestations include immune complex glomerular disease, accelerated progression of CKD, increases in cardiovascular event risk, and lymphoproliferative disorders. Advances in understanding the molecular biology of HCV have ushered in a new era in the treatment of this infection. Second generation direct-acting antiviral agents have revolutionized therapy, with sustained virologic response rates (undetectable viral load 12 weeks after completing therapy) of >90% in most patients. Studies using direct-acting antivirals in patients with CKD and those on dialysis are showing excellent safety and efficacy as well. In this context, it is imperative that nephrologists become familiar with this literature, reviewed here, so that the important decisions, including which patients should be treated and the optimal timing to initiate therapy, are vetted in association with the compounding issues of CKD, ESRD, and kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.